Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry

International Journal of Antimicrobial Agents

Volumn 34, Issue 5, 2009, Pages 446-450

  Vehreschild, Jörg J ^a   Sieniawski, Michal ^a   Reuter, Stefan ^b   Arenz, Dorothee ^a   Reichert, Dietmar ^c   Maertens, Johan ^d   Böhme, Angelika ^e   Silling, Gerda ^f   Martino, Rodrigo ^g   Maschmeyer, Georg ^h   Rüping, Maria J G T ^a   Ullmann, Andrew J ⁱ   Cornely, Oliver A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c Hämatologisch Onkologische Gemeinschaftspraxis Dr Reichert/Dr Janssen ^*  (Germany)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e Onkologikum Frankfurt Am Museumsufer   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h KLINIKUM ERNST VON BERGMANN   (Germany)

ⁱ JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Antifungal prophylaxis; Aspergillosis; Caspofungin; Itraconazole; Stem cell transplantation

Indexed keywords

EID: 69949181584     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.06.025     Document Type: Article

References (29)

1. Maschmeyer G., Haas A., and Cornely O.A. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 67 (2007) 1567-1601
2. Maschmeyer G. The changing epidemiology of invasive fungal infections: new threats. Int J Antimicrob Agents 27 Suppl. 1 (2006) 3-6
3. McNeil M.M., Nash S.L., Hajjeh R.A., Phelan M.A., Conn L.A., Plikaytis B.D., et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 33 (2001) 641-647
4. Maschmeyer G., and Haas A. The epidemiology and treatment of infections in cancer patients. Int J Antimicrob Agents 31 (2008) 193-197
5. Cornely O.A., Bohme A., Buchheidt D., Einsele H., Heinz W.J., Karthaus M., et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 94 (2009) 113-122
6. Maertens J., Raad I., Petrikkos G., Boogaerts M., Selleslag D., Petersen F.B., et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39 (2004) 1563-1571
7. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002) 408-415
8. Walsh T.J., Raad I., Patterson T.F., Chandrasekar P., Donowitz G.R., Graybill R., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44 (2007) 2-12
9. Cornely O.A., Bohme A., Reichert D., Reuter S., Maschmeyer G., Maertens J., et al. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother 61 (2008) 939-946
10. Offner F., Cordonnier C., Ljungman P., Prentice H.G., Engelhard D., De Bacquer D., et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 26 (1998) 1098-1103
11. Fukuda T., Boeckh M., Guthrie K.A., Mattson D.K., Owens S., Wald A., et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 10 (2004) 494-503
12. Avivi I., Oren I., Haddad N., Rowe J.M., and Dann E.J. Stem cell transplantation post invasive fungal infection is a feasible task. Am J Hematol 75 (2004) 6-11
13. Bjerke J.W., Meyers J.D., and Bowden R.A. Hepatosplenic candidiasis-a contraindication to marrow transplantation?. Blood 84 (1994) 2811-2814
14. Sipsas N.V., and Kontoyiannis D.P. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis 42 (2006) 1584-1591
15. Leather H., Boyette R.M., Tian L., and Wingard J.R. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 12 (2006) 325-334
16. Said A., Garnick J.J., Dieterle N., Peres E., Abidi M.H., and Ibrahim R.B. Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient. Pharmacotherapy 26 (2006) 289-295
17. Kuypers D.R., Claes K., Evenepoel P., Maes B., Vandecasteele S., Vanrenterghem Y., et al. Drug interaction between itraconazole and sirolimus in a primary renal allograft recipient. Transplantation 79 (2005) 737
18. Bermudez M., Fuster J.L., Llinares E., Galera A., and Gonzalez C. Itraconazole-related increased vincristine neurotoxicity: case report and review of literature. J Pediatr Hematol Oncol 27 (2005) 389-392
19. Marr K.A., Crippa F., Leisenring W., Hoyle M., Boeckh M., Balajee S.A., et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103 (2004) 1527-1533
20. Walsh T.J., Teppler H., Donowitz G.R., Maertens J.A., Baden L.R., Dmoszynska A., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351 (2004) 1391-1402
21. National Cancer Institute. Common toxicity criteria version 3.0. Washington, DC: United States Department of Health and Human Services; 2003.
22. Ascioglu S., Rex J.H., de Pauw B., Bennett J.E., Bille J., Crokaert F., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34 (2002) 7-14
23. Cornely O.A., Maertens J., Bresnik M., Ebrahimi R., Ullmann A.J., Bouza E., et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44 (2007) 1289-1297
24. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: WHO; 1979.
25. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007;147:573-7. Erratum. Ann Intern Med 2008;148:168.
26. Glasmacher A., Molitor E., Hahn C., Bomba K., Ewig S., Leutner C., et al. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia 12 (1998) 1338-1343
27. Nosari A., Oreste P., Cairoli R., Montillo M., Carrafiello G., Astolfi A., et al. Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion. Am J Hematol 68 (2001) 231-236
28. Cornely O.A., Maertens J., Winston D.J., Perfect J., Ullmann A.J., Walsh T.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356 (2007) 348-359
29. Goodman J.L., Winston D.J., Greenfield R.A., Chandrasekar P.H., Fox B., Kaizer H., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326 (1992) 845-851